Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed and Recurrent Glioblastoma

Interventions

DRUG: [177Lu]Lu-NeoB
DRUG: [68Ga]Ga-NeoB
OTHER: Temozolomide

Sponsor

Novartis Pharmaceuticals